Tirzepatide
Symbol Tz · MW 4814 Da
Dual GIP and GLP-1 receptor agonist with potent metabolic effects.
- Discovered
- 2016
- Half-life
- 5 days
- Approval
- FDA-approved (Mounjaro, Zepbound)
Quick facts
- Category
- Weight Loss
- Route
- Injectable
- Molecular weight
- 4814 Da
- Half-life
- 5 days
- Discovered
- 2016
- Approval status
- FDA-approved (Mounjaro, Zepbound)
Reported effects
- Powerful weight loss
- A1c reduction
- Lipid improvement
Overview
Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide used for type 2 diabetes management and chronic weight management. By targeting two incretin hormone pathways, Tirzepatide helps regulate appetite, insulin response, blood sugar control, and metabolic function. It supports weight loss by helping users feel full, reducing hunger, and improving how the body responds to food intake. Tirzepatide is often discussed as one of the most powerful modern weight loss peptides because of its dual-action mechanism. Its purpose is not simply fat burning, but broader metabolic support through appetite regulation, glucose control, and improved energy balance.
Evidence context
Tirzepatide evidence summary
Human clinical evidence
Tirzepatide has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Tirzepatide may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Tirzepatide as FDA-approved (Mounjaro, Zepbound). The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 2.5–15 mg
- Typical Frequency
- Once weekly
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Tirzepatide.
Internal links
Related peptides
Frequently asked questions
What category is Tirzepatide in?
Tirzepatide is listed in the Weight Loss category on Peptidic.
What route is Tirzepatide associated with?
Tirzepatide is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Tirzepatide approved?
Peptidic lists the approval status for Tirzepatide as: FDA-approved (Mounjaro, Zepbound). Approval details can vary by indication and jurisdiction.
Interested in Tirzepatide?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01